Metabolic dysfunction, especially insulin resistance, is a key risk factor in the early development of AD [40] and several attempts have been made to develop pharmaceutical treatments for AD by managing insulin signaling such as an intranasal insulin spray and GLP-1 agonists. Here, INS is linked to Insulin resistance.